Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid) binds with high affinity to the α 2 δ subunit of voltage-gated calcium channels, exerting analgesic, antiseizure, and anxiolytic activities (Dooley et al., 2007; Field et al., 2006; Taylor et al., 2007) . In 2-year carcinogenicity studies conducted during the development of rodents after administration of pregabalin, treatment-associated increases in hemangiosarcoma occurred in B6C3F1 and CD-1 mice, but not in Wistar rats (Pegg et al., 2012) . In mice, the highest incidence of hemangiosarcoma was observed in liver, spleen, and bone marrow, all hematopoietic tissues with discontinuous endothelium. The tissue distribution and latency of tumor occurrence were similar to those seen for spontaneously occurring hemangiosarcoma in mice, suggesting that tumor induction by pregabalin may involve exacerbation of normal physiologic processes in mice.
Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid) binds with high affinity to the α 2 δ subunit of voltage-gated calcium channels, exerting analgesic, antiseizure, and anxiolytic activities (Dooley et al., 2007; Field et al., 2006; Taylor et al., 2007) . In 2-year carcinogenicity studies conducted during the development of rodents after administration of pregabalin, treatment-associated increases in hemangiosarcoma occurred in B6C3F1 and CD-1 mice, but not in Wistar rats (Pegg et al., 2012) . In mice, the highest incidence of hemangiosarcoma was observed in liver, spleen, and bone marrow, all hematopoietic tissues with discontinuous endothelium. The tissue distribution and latency of tumor occurrence were similar to those seen for spontaneously occurring hemangiosarcoma in mice, suggesting that tumor induction by pregabalin may involve exacerbation of normal physiologic processes in mice.
In routine safety studies of durations ranging up to 1 year, pregabalin had few demonstrable adverse effects in mice, rats, or monkeys. In 2-year carcinogenicity studies in mice, the most remarkable effects of pregabalin treatment were changes in bone marrow and splenic hematopoietic tissues. Many of the observed changes were consistent with a response to blood loss, an anticipated event associated with vascular tumors. However, in rats, a species without hemangiosarcomas, peripheral red blood cell counts (RBCs) were elevated approximately 20% in pregabalin-treated animals compared with the counts in control rats (Pegg et al., 2012) . Additionally, in the 2-year carcinogenicity study, platelet counts were elevated in mice, but were significantly decreased in rats; so, hematologic effects occurred in differentiated patterns in species that either produced or failed to produce tumors in response to lifelong pregabalin treatment. It is well recognized that hematopoiesis and angiogenesis are closely linked. Endothelial cells, the cell type of origin for hemangiosarcomas, are believed to be derived from a common hematopoietic precursor, the hemangioblast (Keller, 2001) . Hematopoietic cytokines and growth factors may also play a role in stimulating endothelial cell proliferation, migration, and differentiation (Aird, 2004) . Given the mouse-specific increases in erythroid cells, macrophages, and platelets, coupled with the finding that hematopoietic tissue is the primary target of pregabalin-induced hemangiosarcomas in mice, these cell types, and their inherently rich source of growth factors, may be relevant to angiogenesis and increased endothelial cell proliferation.
In 2009, a unified mode-of-action (MOA) framework for the induction of hemangiosarcoma by nongenotoxic compounds was proposed. According to this proposal, five components appear to be shared across a diverse set of compounds that induce hemangiosarcoma: hypoxia, dysregulated angiogenesis and/or erythropoiesis, macrophage activation, increased angiogenic growth factors, and increased endothelial cell proliferation (Cohen et al., 2009) . Specifically, agents that induce hemangiosarcoma appear to initiate events that lead to local tissue hypoxia and macrophage activation. These two changes increase angiogenic growth factors. This process is analogous to physiologic angiogenesis, but it is hypothesized that dysregulated angiogenesis occurs because these responses are sustained many times by dysregulated erythropoiesis. Dysregulated angiogenesis leads to endothelial cell proliferation and contributes toward hemangiosarcoma formation.
A series of investigative studies were conducted to determine the MOA for mouse-specific hemangiosarcomas by pregabalin. The first goal of these investigative MOA studies was to establish what could be the initiating event leading to hypoxia. To achieve this goal, the temporal relationship of pregabalin's hematopoietic changes in rodents was studied to determine whether these changes were in fact initiating events or were simply by-products of tumor formation. Potential drivers of tissue hypoxia, including blood gas and pulmonary function, were studied in mice and rats. These studies demonstrated that serum bicarbonate levels were increased after 24 h and this led to an increase in blood pH in mice, but not in rats. Additionally, although both species showed decreased respiration rate in response to pregabalin administration, only rats compensated appropriately by increasing minute volume.
The second objective of this study was to assess whether there was evidence for dysregulated erythropoiesis and increased circulating and/or tissue growth factors relevant to angiogenesis. Pregabalin was shown to increase the number of macrophages in mouse bone marrow, spleen, and liver up to fivefold greater than the control within 1 year. Evidence for dysregulated erythropoiesis in the mouse included accelerated erythropoiesis coupled with eryptosis (suicidal destruction of erythrocytes). Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) were also increased in mouse bone marrow and spleen; and vascular endothelial growth factor receptor 2 (VEGFR2) was elevated in mouse liver following pregabalin administration. These studies confirmed changes that are consistent with the unified MOA framework for induction of hemangiosarcoma by nongenotoxic compounds (Cohen et al., 2009) and showed that the identified changes were species-specific and occurred only in the mouse.
Platelet function studies. Blood samples (citrate anticoagulant) were collected by cardiocentesis and platelet-rich plasma was prepared for platelet-aggregation assessments. Platelet-aggregation analysis was conducted on a ChronoLog Platelet Aggregometer (Havertown, PA). Platelet-rich plasma was prepared by diluting rat whole blood 1:3 and mouse whole blood 1:4 with sterile saline and centrifuging for 20 min at 900  g. Samples were stimulated with 10-µM adenosine diphosphate (ADP) to elicit aggregation.
Platelet activation was assessed in heparinized blood samples using CD62 detection as a marker of surface P-selectin expression. The flow cytometric methodology of Ault (1993) was used to evaluate the extent of platelet activation in control and pregabalin-treated mice and rats. Data were expressed as the percentage of platelets expressing the surface marker P-selectin.
Respiratory and Blood Gas Assessments
Experimental animals and environmental conditions. Female Wistar (Crl:[WI]BR VAF/Plus) rats and female B6C3F1/CrlBR and CD-1 (Crl:CD-1[ICR]BR) mice were obtained from Charles River Laboratories, Portage, MI. Wistar rats and B6C3F1 mice were used for bicarbonate, blood gas, and pulmonary assessments. CD-1 mice were evaluated for pulmonary function only. For arterial blood gas determinations, rats and mice were ordered from Charles River with implanted carotid catheters to facilitate blood collection. Rats were 9 weeks old and weighed 187-242 g at the start of dosing. Mice were 12-13 weeks old and weighed 18-25 g at start of dosing. Rats and mice without catheters were acclimatized to the laboratory environment for a minimum of 6 and 23 days, respectively, prior to initiation of dosing. Dosing of catheterized animals was initiated approximately 2 days after arrival to ensure patency of the catheters for as long a period as possible. Catheterized animals were approximately 6-8 days postsurgery at initiation.
Respiratory assessment. Pulmonary function was assessed in unrestrained animals using whole body plethysmography. Plethysmographs were fitted with flow transducers and a regulated bias airflow of approximately 0.5 l/min was supplied to each. Data generated from the flow transducers were routed through an amplifier to a Ponemah Data Acquisition System. The variables generated from the waveform signal included minute volume, respiratory rate, and tidal volume. Because body weight can influence the volume of respiration, minute volume and tidal volume were also calculated as weight-corrected values.
For Wistar rats and B6C3F1 mice, pairs of animals were tested simultaneously. Each pair consisted of a control and a pregabalin-treated animal, monitored in separate plethysmograph chambers. A subgroup of five control and five pregabalin-treated animals underwent testing on days 2, 8, 15, and 25 with a , 3, 8, 9, 15, and 16 . A longer time period of 120 min was assessed on days 15 and 16 for mice and on days 25 and 26 for rats to determine whether effects persisted longer than 60 min. CD-1 mice were also evaluated for potential respiratory effects. Because the incidence of hemangiosarcomas was much higher in B6C3F1 mice compared with that in CD-1 mice (Pegg et al., 2012) , coupled with the profound respiratory effects in B6C3F1 mice, repeating respiratory assessments in CD-1 mice allowed an opportunity to evaluate respiratory differences between the two mouse strains. A staggered dosing schedule was used for CD-1 mouse assessments, which allowed all mice to be tested on the same day so that combination of data from subsequent days was not necessary. After the experimental period, animals were returned to their home cages. Animals were euthanized at conclusion of experiments. Five-minute and sixty-minute mean values were analyzed for respiratory rate, minute volume, and tidal volume for each species and strain.
Blood Gas Assessments
B6C3F1 mice. Mice were not fasted prior to blood collection. Noncatheterized mice were randomly assigned to a control or a pregabalin-treated group and used for collection of venous blood samples. Mice with implanted carotid catheters were assigned to control or pregabalin-treated groups and were used for assessment of arterial blood gas samples. Blood was collected into heparinized tubes. Venous blood (0.25 ml) was collected by cardiocentesis within 30 s of cervical dislocation. In arterially catheterized mice, blood (~0.05 ml) was drawn and discarded. The subsequent 0.125 ml was analyzed for blood gas parameters. Animals that became debilitated and all animals at the end of the study were humanely euthanized.
CD-1 mice. Blood for determination of venous bicarbonate was collected on days 2 and 15 through cardiac puncture. Full blood gas assessments were not conducted in the CD-1 mouse strain.
Rats. Rats were not fasted prior to blood collection. Blood gases were assessed in both venous blood collected by jugular venipuncture from control and pregabalin-treated, restrained, unanesthetized rats; and arterial blood collected from control or pregabalin-treated rats via implanted carotid catheter. Approximately 0.1 ml of blood was drawn and discarded and then a 0.5-ml aliquot of venous blood was taken for blood gas assessments. In catheterized animals, an ~0.1-ml aliquot of blood was taken and discarded prior to the sample obtained for analysis. Blood was collected into heparinized tubes. All animals were assessed at all time points unless the catheter was occluded and prevented blood collection. The occlusion frequency was minimal and did not affect interpretation of data. Rats were humanely euthanized at the end of the study.
Analytical methodology. Heparinized arterial and venous blood was immediately transferred to an i-STAT blood gas analyzer (Heska Corp., Fort Collins, CO), and then pH, partial pressure of carbon dioxide (pCO 2 ), partial pressure of oxygen (pO 2 ), and levels of sodium and potassium were assessed. Oxygen saturation (sO 2 ) was calculated by the i-STAT. Chloride and bicarbonate values were assessed using a Vitros chemistry analyzer (Johnson & Johnson, New Brunswick, NJ).
Statistical Evaluation
Arithmetic means and standard deviations or standard errors were calculated for all quantitative data. Treatment comparisons were performed on ranktransformed data using Student's t-test applied at the two-tailed 1 and 5% significance levels. All parameters were analyzed separately for each time period.
RESULTS

Retrospective Analysis of 2-Year Carcinogenicity Studies
Bone marrow, spleen, and peripheral blood. In the mouse carcinogenicity studies, pregabalin produced congestion of venous sinuses, erythroid hyperplasia, increased megakaryopoiesis, macrophage accumulation, and hemosiderin deposition in bone marrow and spleen. In contrast, bone marrow smears from pregabalin-treated rats lacked pigmented and nonpigmented macrophages; there was no evidence of erythrophages, megakaryocytes were decreased, and there was no splenic extramedullary hematopoiesis (EMH). RBC was increased in both rats and mice treated with pregabalin for 2 years, although increases were more prominent in rats. Platelet counts were increased in mice and the platelets demonstrated abnormal morphology; however, they were decreased in number but having normal morphology in rats. A full description of the retrospective review is provided in the supplemental section ( Supplementary  table 1; Supplementary fig. 1 ).
Hematologic Changes
Peripheral blood cell counts. Species-specific and age-related changes in hematological parameters were apparent in both untreated mice and rats. In control mice, RBC, reticulocyte count, and WBC remained unchanged from the day 2 assessment through 12 months, whereas platelet counts increased over time in untreated control mice (Table 2 ). In control rats, WBC remained unchanged over time, but RBC increased, and reticulocyte and platelet count decreased. A species-specific directional change was most clearly apparent in the reticulocyte and platelet counts of untreated control animals ( Table 2 ). Pregabalin treatment accentuated normal age-related changes in hematological parameters in rats and mice.
Pregabalin increased RBC in both age-matched mice and rats, but the increases were most pronounced in rats (Table 2) . In B6C3F1 mice, minor increases in RBC (2-7%) were observed within 24 h of pregabalin administration at 5000 mg/kg and were also demonstrable following 6 and 12 months of drug administration at 1000 mg/kg in mice. Although the magnitude of these changes was small, the consistent pattern of increase in these parameters across multiple animals at each time point indicates that the statistical increases in RBC numbers were dependent on treatment. Increases in RBC in rats receiving 900 mg pregabalin/kg ranged from 5 to 11% higher than controls at all time points evaluated (24 h, up to 12 months). In contrast to the lack of effect on reticulocyte counts in mice, pregabalin induced a decrease of 42% in the absolute reticulocyte counts by day 8 (data not shown) and the reticulocyte counts remained decreased by a similar percentage in rats at day 29 and by approximately 23% at 6 and 12 months (Table 2) .
Pregabalin exacerbated the normal age-related direction of change in platelet count, thereby further increasing platelet counts, compared with controls in mice, and decreasing the platelet counts in rats (Table 2 ). In pregabalin-treated mice, platelet counts increased 12% by day 29, remained elevated at 6 and 12 months, but in rats remained decreased (up to 20%) to 12 months. Morphologic and functional abnormalities were present in platelets of B6C3F1 mice treated for 1 month with pregabalin administration, and altered platelet morphology persisted for 12 months. Erythrocyte morphology changes in pregabalin-treated mice were restricted to schistocyte formation in mice containing histologically identifiable hemangiosarcomas. Schistocytes were only observable in 12-month-treated mice containing tumors, but not at earlier time points in these same animals, demonstrating that schistocytes were a reliable biomarker of hemangiosarcoma formation. In rats, erythrocyte morphology and platelet morphology and function remained unchanged from controls through 18 months of exposure (Table 2; Supplementary table 1) .
Pregabalin also had a species-specific effect on WBC, increasing WBC in treated mice but having no effect in treated rats (Table 2) . Compared with time-matched controls, WBC was increased up to 46% in pregabalin-treated mice and was similar in magnitude from 24-h through 12-month assessments. Peripheral leukocyte differentials in pregabalin-treated mice showed increases in absolute numbers of all major cell types (neutrophils, lymphocytes, and monocytes), but the relative distribution of cell types remained similar to controls (data not shown).
Platelet aggregation results in mice and rats. Pregabalin produced a signature effect on platelet-aggregation patterns in mice. In control mouse platelet-rich plasma (PRP), ex vivo addition of ADP stimulated 70-80% of platelets to aggregate (Fig. 1A) . In contrast, although PRP from pregabalin-treated mice initially responded to the exogenous addition of ADP, the platelets subsequently disaggregated (Fig. 1B) . Although the presence of platelet aggregates in peripheral blood coupled with depressed platelet aggregation in ex vivo assays may appear contradictory, these aberrations in platelet aggregation indicate defective secondary ADP-dependent aggregation and suggest that platelet ADP content has been depleted in vivo. The platelets in pregabalin-treated mice are hypogranular or agranular, which is consistent with in vivo platelet activation with subsequent degranulation. Additionally, platelet degranulation renders platelets ADP-depleted, and explains the lack of a secondary response to exogenous ADP under ex vivo conditions because the secondary wave is attributable to release of internal ADP stores from granules. Decreases in maximum platelet aggregation were observed in mice at 1, 6, and 12 months (Table 3) . In contrast, there were no effects of pregabalin on maximum platelet aggregation and no evidence of platelet disaggregation in in vitro assays of platelets from rats given 900 mg/kg for up to 18 months (Table 3) . Thus, pregabalin-induced alterations in platelet aggregation were seen only in mice.
Platelet activation results in mice and rats. In mice, pregabalin induced persistent increases in platelet activation (P-selectin expression) at 1000 mg/kg, which were apparent at 1, 6, and 12 months of treatment, the last time point that P-selectin expression was evaluated (Table 4) . No consistent effects on P-selectin expression were observed after 50 or 200 mg/kg pregabalin was administered to mice for up to 12 months. The increase in platelet activation at 1000 mg/kg dose reversed 4 weeks after cessation of treatment (data not shown). In contrast, platelet activation (P-selectin expression) was not increased in rats treated with pregabalin at 900 mg/kg for up to 18 months (Table 4) .
Bone marrow TNC.
As body mass increases with normal growth and maturation, the total number of nucleated cells within the bone marrow should, and did, increase over time in both species (Table 5) . However, pregabalin treatment produced a species-specific effect on bone marrow cellularity in rats and mice. Bone marrow TNC remained unchanged or slightly increased from controls, and highly cellular, in pregabalin-treated mice from 24 h through 12 months (Table 5 ). In contrast, TNC in rats was statistically decreased by 40 and 36% at 6 and 12 months of treatment, respectively. This decrease in bone marrow cellularity correlates with the decrease in peripheral reticulocyte and platelet counts in rats. Wistar rat (900 mg/kg) 1 month 15.4  3.8 14.9  5.2 13.3  2.0 23.5  6.9* 7.9  4.5 7.4  5.0 6 months 10.0  1.4 10.2  1.0 14.8  2.5* 16.2  1.0* 8.6  3.2 6.0  3.4 12 months 17.3  5.8 15.2  4.9 17.1  6.9 24.8  9.5* 10.2  4.6 10.6  5.4
Note. n  10 for mice, and 5 for rats. *Statistically significant, p  0.05. Note. n  10 for mice, and n  5 for rats. a 5000 mg/kg/day for 2 and 29 days; 1000 mg/kg/day for 6 and 12 months. *Statistically significant, p  0.05; **p  0.01. Downloaded from https://academic.oup.com/toxsci/article-abstract/128/1/22/1637618 by guest on 14 March 2019
Bone marrow myeloid-to-erythroid ratio. Pregabalin produced species-specific effects on the myeloid-to-erythroid (M:E) ratio in mice and rats. The M:E ratio decreased in mice receiving pregabalin as early as 24 h after drug administration and remained depressed for up to 12 months (Table 5 ). Mean M:E ratios ranged in magnitude from 0.93 to 1.09 in pregabalin-treated mice, compared with 1.61-2.01 in control animals over the 12-month treatment period. The change in M:E ratio in pregabalin-treated mice was due to both a decrease in absolute myeloid cells and an increase in absolute erythroid cells. The magnitude of increase in erythroid cells in pregabalin-treated mice was 38% at 24 h and this magnitude was sustained at other sampling points over the 12-month duration of the study (Table  5 ). Histologic examination of mice revealed congestion in the bone marrow and spleen with accumulation of nonnucleated, mature erythrocytes and hemosiderin-laden macrophages after only 1 month of pregabalin administration ( Fig. 2A , untreated control; and Fig. 2B , 1000 mg/kg/day pregabalin, bone marrow). The extent of congestion and iron-laden macrophage accumulation in bone marrow and spleen increased with duration of pregabalin exposure (Supplementary fig. 1 ).
In rats, M:E ratio was unchanged through the 12 months of pregabalin treatment (Table 5 ). In contrast to mice, myeloid, erythroid, and lymphoid cells were decreased at 6 and 12 months, consistent with the overall decrease in rat bone marrow cellularity (TNC). The characteristic histopathologic observation of hypocellularity, coupled with adipocyte accumulation, in the bone marrow of pregabalin-treated rats is shown in Figure 2 (C, untreated control; and D, 900 mg/kg/day pregabalin).
Bone marrow macrophages. Bone marrow macrophages are typically a normal but low-frequency cell type in the bone marrow. In untreated animals, the percentage of macrophages increased eightfold in control mice and twofold in control rats from the day-2 assessment to the 12-month assessment (Table 5). This demonstrates a greater propensity for bone marrow macrophage to increase in the untreated mouse than in the rat. Pregabalin also exacerbated the species-specific and agerelated effects on macrophages. In mice, bone marrow macrophages increased from 0.04% of bone marrow cells on day 2 to 2.28% of cells at 12 months, a 57-fold increase over time and an approximately 5-fold increase compared with age-matched control mice (Table 5 ). In contrast, rats treated with pregabalin showed no increase in bone marrow macrophages, either compared with age-matched controls or between the day-2 and 12-month assessments (Table 5) .
Additionally, in pregabalin-treated mice macrophages were in an activated state, as evidenced by the presence of erythrophages, macrophages containing intact erythrocytes. Erythrophages were present in 30-80% of pregabalin-treated mice at all time points during the 28-day period and in 100% of the pregabalin-treated animals by 6 months (Fig. 3A , untreated control; Fig. 3B , 1000 mg/kg/day pregabalin). Phagocytized erythrocytes in pregabalin-treated mice were intact in many cases, suggesting that they were identified and engulfed prior to lysis via some surface alteration that made them recognizable by the bone marrow macrophages (Fig. 3B) . In contrast, only a single control mouse demonstrated bone marrow erythrophages on day 8, showing that stimulation of bone marrow erythrophagocytosis in mice was related to treatment. Erythrophages were absent in all control and pregabalin-treated rats.
Assessment of tissue iron. Prussian Blue staining of bone marrow and spleen sections confirmed the presence of increased iron deposition in pregabalin-treated mice, consistent with the presence of hemosiderin-laden macrophages (Fig. 3C,  untreated control; Fig. 3D , 1000 mg/kg pregabalin). Qualitative assessment of tissue iron in liver sections was similar in control and pregabalin-treated mice. There was no evidence of iron accumulation in rat liver, spleen, or bone marrow sections (data not shown).
Serum growth factors. Serum levels of VEGF and TPO were measured in mice administered pregabalin for 12 months, and levels of PDGF were measured in mice exposed for up to 24 months. Pregabalin treatment did not affect VEGF or TPO concentrations in either B6C3F1 mice or Wistar rats (data not shown). At 12 and 24 months of treatment, there were no effects on PDGF concentrations in the serum of mice administered 50 or 200 mg/kg pregabalin. PDGF concentrations were increased after 12 months of treatment with 1000 mg/kg pregabalin (mean  standard deviation: 1257  535 pg/ml in control mice vs. 4882  4966 pg/ml at 1000 mg/kg). After 24 months of treatment, pregabalin increased PDGF by 47% at 1000 mg/ kg (data not shown). PDGF secreted from tumors may have contributed to the measured increase, particularly at 24 months because tumors were first identified in this investigative study at 18 months of exposure. There was no effect of pregabalin treatment on serum PDGF up to 18 months (data not shown).
Tissue growth factor immunolabeling. Pregabalin treatment resulted in an increase in bone marrow and splenic macrophages and erythroid precursors and these cells were strongly positive for bFGF ( Fig. 4A, control; Fig. 4B , 1000 mg/kg pregabalin) in of mice treated for 12 months. Increased bFGF staining was also evident at 6 months in mouse bone marrow and spleen, and the bFGF signal was more intense following 12 months of exposure. Megakaryocytes showed little or no evidence of increased bFGF staining in mice (Fig. 4B, white arrow) , but robust bFGF staining was observed in other cell types that were morphologically consistent with macrophages and erythroblasts. In rats, there was no difference in bFGF staining between untreated controls and animals receiving 900 mg/kg pregabalin for up to 18 months (not shown) in any of the tissues examined.
Pregabalin increased levels of VEGF in the spleens of mice after 6 months of treatment at 5000 mg/kg, based upon immunohistologic labeling (Fig. 4C, untreated control; Fig. 4D , 1000 mg/kg/day pregabalin). Megakaryocytes and macrophages were strongly positive for VEGF staining. VEGF expression was also increased in spleen and in sternal bone marrow at 1000 mg/kg, following one year of pregabalin administration. Immunolabeling was restricted to hematopoietic cells in the red pulp, including megakaryocytes, the precursor cells that generate peripheral platelets. VEGF immunolabeling in mouse bone marrow was less intense than that in spleen, probably due to extensive tissue processing and bone decalcification; however, increased staining relative to controls was seen in both femoral and sternal bone marrow of treated mice after 12 months of pregabalin exposure (not shown). Pregabalin-induced changes in VEGF were not demonstrable in mouse liver. In contrast to the findings in mice, there were no pregabalin-related changes in Immunolabeling of bFGF, VEGF, and VEGFR2 in mice. VEGF in bone marrow of (A) age-matched control; and (B) mouse given 1000 mg/kg for 12 months. Punctate staining demonstrates intracellular accumulation of bFGF. Megakaryocytes demonstrate very little staining. In contrast, pregabalin produces robust bFGF staining in other cell types, probably macrophages and erythroblasts (×10). VEGF in spleen of (C) age-matched control; (D) mouse given 1000 mg/ kg for 6 months. VEGF concentration was prominent in megakaryocytes, but was also increased in generalized red pulp areas. Bone marrow gave a similar staining pattern (×40). VEGFR2 (Flk-1) immunolabeling of liver in (E) a control B6C3F1 mouse and (F) mouse receiving 1000 mg/kg/day pregabalin for 12 months (×10).
the VEGF in bone marrow, spleen, or liver of rats administered 900 mg/kg pregabalin for up to 12 months.
Tissue growth factor receptors. In female mice administered pregabalin for 12 months, VEGFR2 (Flk-1) immunolabeling was increased in endothelial cells of liver at 1000 mg/kg but not at 50 or 200 mg/kg (Fig. 4E, untreated control; Fig. 4F , 1000 mg/kg/ day pregabalin). Pregabalin did not alter Flk-1 immunolabeling in liver of rats given 900 mg/kg for 12 months (not shown).
Serum bicarbonate. Mean serum bicarbonate concentrations were consistently elevated in B6C3F1 mice and Wistar rats as early as 24 h following the administration of pregabalin in the diet and remained elevated for the duration of the study ( Table 6) . Mean increases were similar in mice (up to 29%) and rats (up to 27%) and were evident in both arterial and venous samples. In CD-1 mice, bicarbonate values were only assessed in venous blood on days 2 and 15. Elevations in bicarbonate were also observed in both time points in this alternate strain of mouse (Table 6) .
Effects on Pulmonary Function
Respiratory rate. In both control and pregabalin-treated mice and rats, respiratory rates declined over the 60-min interval that data were collected from the plethysmographs due to acclimatization of animals to the chamber environment. This decrease in respiratory rate was anticipated because respiratory rates are typically elevated in an agitated state and are decreased in a relaxed state. However, relative to control, the respiratory rates of pregabalin-treated animals were further suppressed at each 5-min interval over the course of the 60-min collection periods. To standardize for the accommodation effect of the plethysmograph chamber, 60-min mean values were calculated to obtain an overall value for the effect of pregabalin on respiratory rate, minute volume, and tidal volume. In addition, values are represented as percent of control to standardize for innate species differences in initial respiratory rate, minute volume, and tidal volume.
In B6C3F1 mice, 60-min mean respiration rates were decreased by 34, 27, 25, and 17% after pregabalin administration on days 2/3, 8/9, 15/16, and 25/26, respectively. In CD-1 mice, 60-min mean respiration rates were decreased by 19, 15, 22, and 20% on days 2, 8, 15, and 25, respectively. In pregabalintreated rats, the 60-min mean respiration rate was similar to that of controls on days 2/3 but decreased by 26, 28, and 19% on days 8/9, 15/16, and 25/26, respectively (Table 7) . B6C3F1 mice showed a rapid and pronounced decrease in respiratory rate within 24 h of pregabalin administration. CD-1 mice also showed a decrease in respiratory rate within 24 h of pregabalin administration, but the effect was approximately half the magnitude of that observed in B6C3F1 mice. In contrast, rats showed no difference in respiratory rate following 24 or 48 h (day 2/3) of pregabalin treatment. However, by day 8, the respiratory rate was also statistically decreased in rats. The magnitude of decrease in respiratory rate was similar in rats and both strains of mice by day 25 and remained approximately 20% less than in untreated controls (Table 7) . (Table 7) . In rats, 60-min mean minute volumes were statistically decreased (by 20%) on days 8/9 only, demonstrating a compensatory increase in minute volume and reversal by day 15. When minute volumes were corrected for body weight, mice clearly demonstrated a treatment-associated decrease in weighted minute volume, whereas there was no effect on weighted minute volume in rats beyond day 15 (Table 7) . Furthermore, following 22 months of 1000 mg/kg pregabalin administration in diet, mice continued to show a 13% decrease in minute volume, demonstrating that the effects on minute volume were sustained throughout the lifespan of the B6C3F1 mouse (data not shown).
Tidal volume. To provide adequate tissue oxygenation, compensatory increases in tidal volume typically accompany decreases in respiratory rate. As rats relaxed (and often fell asleep) in the plethysmograph chamber, their respiration rates decreased and tidal volume increased, as expected (Fig.   5A ). Tidal volumes in pregabalin-treated rats were increased compared with untreated rats on days 8, 15, and 25, showing the anticipated compensatory response to respiratory depression (Fig. 5A, day 25 shown) . Although B6C3F1 mice also showed decreased respiratory rate as they became acclimatized to the chambers, they failed to show an increase in tidal volume in either control or pregabalin-treated animals (Fig. 5B) . Tidal volumes were unchanged from controls in B6C3F1 pregabalintreated mice at any of the time points ( Fig. 5B; day 25) . CD-1 mice showed a similar pattern of decreasing tidal volume with decreasing respiration rate (Fig. 5C.) However, unlike B6C3F1 mice, tidal volumes in CD-1 mice were statistically increased in pregabalin-treated animals compared with untreated controls from day 2 through day 25 (Fig. 5C, days 2, 18, 15, and 25) . Therefore, CD-1 mice have a compensatory response in tidal volume that is not apparent in B6C3F1 mice.
Blood gases in B6C3F1 mice and Wistar rats: pCO 2 assessments. In control animals, mean pCO 2 values were lower in mice than in rats (Table 8 ). This is consistent with a higher respiratory rate in mice, which facilitates greater CO 2 expulsion. Pregabalin increased mean arterial pCO 2 in mice and rats. Mean pCO 2 values ranged from 15 to 23% higher in mice and 17 to 39% higher in rats over the 1-month assessment period (Table 8) . Mean venous pCO 2 values are expected to be slightly higher than arterial pCO 2 values, and this was evident in untreated rats (Table 8 ). However, in control mice, venous pCO 2 values were substantially higher than arterial values (Table 8) . Mean venous pCO 2 values in pregabalin-treated rats were unchanged from those of controls on day 2, but were significantly elevated by 11, 19, and 22% when compared with control rats on days 8, 15, and 29, respectively (Table 8 ). In contrast, in pregabalintreated mice, venous pCO 2 was not statistically increased at any time point compared with concurrent untreated control mice; and on days 8 and 15, it was actually less than the values in untreated mice (Table 8) . Persistent elevations in arterial and venous pCO 2 in rats demonstrate the appropriate compensatory response to elevated baseline levels of serum bicarbonate. In contrast, smaller increases in arterial pCO 2 , coupled with lack of increases in venous pCO 2 , demonstrate that B6C3F1 mice fail to appropriately increase CO 2 concentrations to balance the elevation in serum bicarbonate.
Blood pH. Mean arterial and venous pH values were increased in treated B6C3F1 mice on day 8 and thereafter, but were unaffected in treated rats (Table 8 ; venous pH was similar to arterial pH, not shown). Because the mean increases were small, individual blood pH values from control and pregabalin-treated animals over all time intervals were tabulated using increments of 0.05 pH units to more closely evaluate this phenomenon. The percentage of animals within each 0.05 pH unit increment for arterial blood, venous blood, and combined data were used to create pH-distribution curves. The distribution was shifted to the right (more basic) in pregabalin-treated mice, and a representative plot of the effects of pH in arterial blood is given in Figure 6A . The 50% peak distribution occurs in the pH range of 7.20-7.25 in control mice compared with 7.30-7.35 in pregabalin-treated mice. Additionally, pH values > 7.45 were not observed in any control mouse but were present in the pregabalin-treated group. Individual blood pH values in control and treated mice ranged from 7.02 to 7.54 (Fig. 6A ), which would be considered an extremely broad variability in blood pH relative to other species, including rats. In contrast, pH in rats was more tightly regulated and pregabalin treatment shifted the pH distribution to the left in rats, but with no overall effect on blood pH (Fig. 6B) . The very minor movement toward a more acidic environment in rats is consistent with decreased respiratory rates and accumulation of CO 2 in this species. In contrast, mice sustain a chronic relative metabolic alkalosis, as demonstrated by a sustained increase in blood pH.
Electrolytes. Pregabalin causes significant decreases in chloride values in both rats and mice (Table 8) . A species-specific difference in chloride concentrations was apparent in untreated control rats and mice. Untreated control mice had substantially higher chloride values than untreated control rats, consistent with the relatively acidotic blood pH in mice (Table 5 ). In mice treated with pregabalin, the magnitude of chloride changes was larger than that in the rat and ranged from 3 to 9 mmol/l. Decreases in chloride were an anticipated change due to the increases in HCO 3 observed in both species because retention of HCO 3 -should be accompanied by a decrease in Cl -to balance anion composition. Sodium and potassium remained unchanged in rats. Minor decreases in sodium were observed in mice on days 8, 15, and 29 in arterial samples only, but not in rats (not shown).
DISCUSSION
Lifelong pregabalin administration in mice resulted in increased incidence of hemangiosarcomas that occurred in several tissues, but were most prevalent in bone marrow, spleen, and liver, all hematopoietic organs in rodents (Pegg et al., 2012) . In a retrospective analysis of the clinical pathology data and spleen and bone marrow changes from 2-year carcinogenicity studies, there was evidence that dysregulated erythropoiesis occurred in mice but not in rats. Dysregulated erythropoiesis was defined as development of a reactive (i.e., highly proliferative) bone marrow with evidence of simultaneous increased production and destruction of erythrocytes (eryptosis) in mice. In addition, there were increases in megakaryopoiesis and splenic EMH that increased with exposure time to pregabalin. These findings were prominent by the end of the 2-year carcinogenicity studies in both B6C3F1 and CD-1 mouse strains. In rats, a species negative for pregabalin-induced hemangiosarcomas or any other tumor type at comparable exposures, a decrease in bone marrow cellularity was observed, with no increases in erythroblasts, megakaryocytes, or erythrophages. Although these effects were hypothesized to be associated with causality, they could also be due to the presence of the hemangiosarcoma. Hence, a series of investigative studies were conducted in both mice and rats with exposures ranging from 24 h to nearly 2 years to assess whether these changes could play a role in hemangiosarcoma formation.
Key elements of the pregabalin MOA for hemangiosarcoma formation in mice are outlined in Figure 7 . This MOA is consistent with a unified MOA framework for induction of hemangiosarcoma by nongenotoxic compounds, proposed by Cohen et al. (2009) . Agents that induce hemangiosarcoma all appear to initiate events that lead to local tissue hypoxia.
Pregabalin increased serum HCO 3 in B6C3F1 mice, CD-1 mice, and Wistar rats within 24 h of drug administration in diet. The increase in bicarbonate in rodents treated with pregabalin triggered a compensatory decrease in respiration in both rats and mice. Wistar rats and B6C3F1 mice showed the expected and corresponding compensatory increase in arterial pCO 2 . The timing of increases in HCO 3 and pCO 2 confirmed that elevations in HCO 3 were primary and that increases in pCO 2 were compensatory in nature. Rats normalized their minute volume by increasing the depth of respiration within the first 2 weeks of drug exposure and retained a stable pH over the course of this study. However, in B6C3F1 mice, respiratory compensa-tion and the production of CO 2 were inadequate to balance the increased levels of serum bicarbonate, leading to a sustained relative alkalosis that was not present in rats. In CD-1 mice, the magnitudes of respiratory rate and minute-volume depression were substantially less than those of the B6C3F1 mice. CD-1 mice also have a compensatory increase in tidal volume that was not apparent in B6C3F1 mice. Pulmonary effects in CD-1 mice were intermediate between those observed in B6C3F1 mice and Wistar rats. Although only correlative, the incidence of hemangiosarcoma formation is also less in CD-1 mice compared with B6C3F1 mice, which is consistent with the magnitude of these changes (Pegg et al., 2012) .
Blood pH ranges generated in this study were 7.07-7.41 in untreated B6C3F1 mice and 7.49-7.60 in untreated rats compared with the reported ranges of 7.35-7.45 for humans. The low pH obtained in mice were reproducible in large numbers of mice (> 100). These low blood pH values were also independently generated in 40 strains of mice at Jackson Laboratories. In the Jackson Laboratory evaluation, the mean pH for all strains of mice was 7.21 for females and 7.19 for males, with an extreme low pH value of 7.05 and an extreme high pH value of 7.33 (http://phenome.jax.org/db/qp?rtn=views/ measplot&brieflook=10322). These values are consistent with the pH values obtained in untreated controls in the current study and suggest that under untreated conditions, mice demonstrate a relative metabolic acidosis compared with other species. The inherently low blood pH value in mice would improve their ability to oxygenate tissues, thus meeting the high metabolic demand for oxygen in the mouse. The inherently acidic blood pH in mice allows a shift in the oxygen-dissociation curve and improves oxygen release from hemoglobin due to the Bohr effect. Because metabolic rate is inversely related to body mass, mice require and consume significantly more oxygen per unit mass than rats or humans (Hall, 1966) . Mouse hemoglobin is inherently more sensitive to pH effects on the binding and release of oxygen than most other species examined, and the magnitudes of the pH effects on the O 2 -dissociation curve for mice are correspondingly greater (Schmidt-Nielson and Larimer, 1958; Riggs, 1960 ). Pregabalin's ability to increase pH and elevate sO 2 values in mice demonstrates pregabalin's potential to impede normal oxygen delivery to tissues in the mouse, a process not evident in the rat. Evidence for local tissue hypoxia and increased endothelial cell proliferation are described in the companion paper . Respiratory rate is markedly different among species. In humans, the normal respiratory rate is ~12-15 breaths/min (Guyton, 2000) . In contrast, in this study, the respiratory rate in rats at rest was approximately 94 breaths/min. Respiratory rate in mice was approximately 200 breaths/min under resting conditions. Arterial pCO 2 values are inversely related to the respiratory rate. As such, for higher respiratory rates, the pCO 2 values are lower. Reference ranges across species confirm this, showing that pCO 2 in humans (35-45 mmHg; Toffaletti, 2001 ) > rats (29-39 mmHg, this study) > mice (13-28 mmHg, this study). It is plausible that the greatly elevated respiratory rate in mice attenuates increases in pCO 2 because more carbon dioxide may be expelled. This could account for the inadequate increases in pCO 2 in pregabalin-treated B6C3F1 mice, which contribute to a sustained metabolic alkalosis in mice alone (Fig. 7) .
Assessment of tidal volume in rats and mice demonstrated that a basic difference in respiratory physiology exists between the two species. Rats demonstrated a pattern of tidal volume consistent with that of humans-rapid but shallow breathing under agitated conditions but increased tidal volumes under relaxed conditions-demonstrating deeper breathing with lower respiration rates. Both B6C3F1 and CD-1 mice demonstrated uncharacteristic changes in tidal volume (even under control conditions), showing increased depth of respiration during hyperventilation and a return to more shallow breathing during the relaxed state. The presence of strain-dependent breathing patterns in mice and this rapid shallow-breathing pattern has been previously identified in B6 and C3 strains (Tankersley et al., 1994 (Tankersley et al., , 1997 and the B6C3F1 progeny showed even more pronounced reductions in lung volume and tidal volume than the B6 parent strain (Tankersley, 2000; Tankersley et al., 1999) . The B6C3F1 mice has been hypothesized to be characterized by a hypoxic hypoventilatory phenotype because it inherits a small lung volume from the B6 progenitor and a low ventilator response from the C3 progenitor (Soutiere and Tankersley, 2001; Tankersley, 2000) . Because respiratory function varies among mouse strains, it is not surprising that it also varies among species.
Production of tissue hypoxia is determined by the balance of factors that lead to ischemia and the compensatory factors that ameliorate these conditions. Rats treated with pregabalin show a modest decrease in pO 2 , which suggests that they too could experience hypoxia. However, they also normalize minute volumes (allowing greater air exchange at the alveolar surface), increase tidal volume, decrease venous sO 2 (demonstrating an improved ability to release oxygen to tissues), and increase peripheral erythrocyte counts to allow greater oxygen delivery. In contrast, B6C3F1 mice show no effect of pregabalin on pO 2 values, but demonstrate a chronic increase in blood pH and increase in venous sO 2 , associated with a reduction in oxygen delivery from hemoglobin. Additionally, B6C3F1 mice show a sustained decrease in minute volume throughout their lifespan and fail to mount a significant erythrocyte response. Therefore, rats demonstrate expected accommodation, but mice do not.
Moreover, factors that increase pH activate Na/H exchangerstimulated oxidant production, which promotes endothelial cell injury (Cutaia et al., 2002) . Thus, changes in pH in the mouse have the potential to alter endothelial cell signaling and/or otherwise damage endothelial cells.
B6C3F1 control mice also demonstrated chloride values (113-124 mmol/l, inhouse reference ranges) that are markedly elevated compared with humans (99-110 mmol/l; Toffaletti, 2001 ) and rats (94-106 mmol/l; in-house reference ranges). Other investigators have reported chloride elevations in mice ranging from 110 to 125 mmol/l (Serfilippi et al., 2003; Wolford et al., 1986) . In contrast, rats had chloride values consistent with those found in humans (104 mmol/l; Wolford et al., 1986) . The chloride values observed in control mice would be considered hyperchloremic in other species. Chloride excess (hyperchloremia) is often associated with metabolic acidosis, whereas decreases in chloride help sustain alkalosis. The observations of low pH, low HCO 3 , and high chloride in B6C3F1 control mice are consistent with a preexisting metabolic acidosis in this species. Acidosis is known to facilitate the release of oxygen from erythrocytes (Sherwin, 2003; Toffaletti, 2001) and may provide a mechanism for meeting the high metabolic requirements and oxygen demands of the mouse.
Pregabalin treatment also enhanced bone marrow and splenic erythropoiesis in mice and increased bone marrow erythrophage numbers within 24 h of treatment initiation. The exact cause for the dysregulated erythropoiesis that occurs in mice administered pregabalin is unclear. However, there are a few physiologic processes that drive such rapid increases in bone marrow erythrocyte production. Decreased tissue oxygenation is one of those limited processes consistent with the hypothesis that oxygen release is impaired by the increased blood pH in mice.
Hematopoiesis in mice differs substantially from that in other species. The basal rate of erythropoiesis in mice, based on erythrocyte count and lifespan, is approximately twice the rate in rats and is 10-12 times that of humans (Moore, 2000a (Moore, , 2000b Ryan, 2001) . Platelet production in mice and rats is comparable and is 10-to 13-fold higher than that in humans (Moore, 2000a (Moore, , 2000b Ryan, 2001) . Highly distinctive differences between mice and other species are that hematopoiesis in murine bone marrow is not downregulated with age. Additionally, EMH within the spleen plays a prominent role in hematopoiesis and is a normal physiologic finding in adult mice but occurs only during fetal development or under pathologic conditions in large animals, including humans. Bone marrow in mice is highly cellular throughout life (Chen, 1971; Moore, 2000a) , whereas cellularity of bone marrow decreases with age in rats (Cline and Maronpot, 1985) and humans (Hartsock et al., 1965) as adipocytes replace hematopoietic tissue. The extremely high cell density of mouse bone marrow probably plays a role in the elevated proliferative rates, as proliferation is largely regulated by cell-cell contact (Rich et al., 1998) . Furthermore, pregabalin increased the absolute numbers of three cell types in mouse bone marrow: erythroblasts, macrophages, and megakaryocytes. Architecturally, these three cell types are in direct contact with the endothelial cells of the vascular sinus (Abboud and Lichtman, 2001) , and as a result, they can contribute to increased endothelial proliferation and nongenotoxic carcinogenesis in mice through the growth factors they require for their own proliferation and those they release during activation. It is plausible that an enhanced proliferative environment in the bone marrow and spleen in mice could also result in increased proliferation of endothelial cells because endothelial cells and hematopoietic cells are derived from the same stem cell precursor, the hemangioblast (Keller, 2001) . Hence, these changes, coupled with macrophage activation, could contribute to the development of hemangiosarcoma formation in the bone marrow and spleen of mice.
Increased and activated macrophages are considered another key component of the MOA for pregabalin's ability to produce hemangiosarcomas in mice (Fig. 7) . Pregabalin increased macrophage numbers in liver, spleen, and bone marrow, coupled with increased iron accumulation in bone marrow and spleen. Importantly, these changes were not observed in rats. Pregabalin induces suicidal death or eryptosis of bone marrow erythrocytes as evidenced by time-dependent increases in erythrophages. Eryptosis is the premature death of newly formed erythrocytes. All erythrocytes undergo a normal senescence, whereby phosphatidylserine becomes exposed on the cell surface allowing recognition by phosphatidlyserine receptors on macrophages (Boas et al., 1998) . This leads to engulfment and degradation of aged erythrocytes, a process that typically occurs in liver and spleen (Bratosin et al., 1998) . In contrast, eryptosis in bone marrow is an unexpected and pathologic event (Fishman, 2000) , because erythrocytes are produced but not commonly destroyed in this organ. Bone marrow eryptosis following pregabalin administration was observed only in mice and not in rats or monkeys (data not shown). Interestingly, eryptosis has also been reported in mice with fenretinide (retinoic acid), another compound known to produce mouse-specific hemangiosarcomas (Olivier et al., 2008) . Interestingly, bicarbonate administration in water produced eryptosis in the bone marrow of mice but not in rats (unpublished data), suggesting species specificity and a link of HCO 3 elevation and erythrophage production in mice. Eryptosis is at least partially attributable to simulation of Ca +2 entry (Kaestner and Bernhardt, 2002; Lang et al., 2003) following activation of Ca +2 -permeable cation channels. Calcium entry scrambles the erythrocyte membrane, exposing phosphatidylserine on the cell surface and potentiating erythrophagocytosis. Because pregabalin modulates neurotransmission through binding at the α2δ subunit of voltage-gated Ca +2 channels, it is possible that bone marrow eryptosis in pregabalin-treated mice is driven by effects on Ca +2 channels. The association of enhanced erythropoiesis and macrophage production with hemangiosarcoma formation in mice has been reported for other compounds. The glycol ether, 2-butoxyethanol (2-BE), which is used in brake fluid, commercial coatings, and cleaners and was a major component of the dispersants contained in the Gulf oil spill, is one of the most well-studied compounds in this regard. Intravascular hemolysis is the primary toxicity for 2-BE (Ghanayem and Sullivan, 1993) , and although both rats and mice demonstrate hemolysis upon 2-BE administration, only mice develop hemangiosarcomas (National Toxicology Program [NTP] 2000) . It has been suggested that increased uptake of damaged erythrocytes by erythrophages and Kupffer cells allows iron accumulation, induces release of cytokines and reactive oxygen species from Kupffer cells, and promotes DNA damage to endothelial cells, and thereby enhances endothelial cell proliferation, formation of preneoplastic endothelial cells, and finally transformation into hemangiosarcomas (Gift, 2005; Klaunig and Kamendulis, 2005 [AU: Please note the revised year.]; NTP, 2000; Nyska et al., 2004; Siesky et al., 2001; Xue et al., 1999) . Similarly, phenylhydrazine (PHZ) induces hemolysis and hemangiosarcoma formation in mice but not in rats (Toth and Shimizu, 1976) . Although pregabalin does not produce intravascular hemolysis, it causes increases in erythrophages in mice; so similar to 2-BE and PHZ, pregabalin causes a progressive accumulation of bone marrow and splenic iron in mice. Therefore, the potential for both release of reactive oxygen species related to erythrophages and ironrelated damage to endothelial cells is a plausible contributor to hemangiosarcoma formation in pregabalin-treated mice. The presence of hemosiderin deposits in spleen and bone marrow are consistent with this hypothesis.
Bone marrow and splenic assessments are problematic as readily assessable biomarkers of hemangiosarcomas. Fortunately, morphologic and/or functional changes in hematopoietic cells can also serve as biomarkers of hemangiosarcomas and/ or earlier effects on vascular endothelial cells. Schistocytes are fragments of erythrocytes that occur as cells flow through damaged small vessels. Erythrocytes are literally torn and schistocytes circulate as pieces of red blood cells. Schistocytes have been reported in dogs with hemangiosarcomas (Ng and Mills, 1985) and are therefore a late-stage biomarker for the presence of these vascular tumors. Schistocytes were observed in B6C3F1 and CD-1 mice receiving ≥ 1000 mg/kg for 24 months in the carcinogenicity studies and in some animals, as early as at 12 months of drug administration but not at 1 or 6 months of exposure (Table 2; Supplementary table 1) . This demonstrates that schistocyte formation is a late-stage biomarker of hemangiosarcomas in mice treated with pregabalin. Rats treated for up to 2 years, monkeys treated for up to 1 year, and humans treated for up to 3 years (data not shown for monkeys and humans) showed no evidence of schistocyte formation.
An early marker of endothelial effects that occur prior to tumor formation would be highly beneficial in assessing the potential tumor risk to humans. Similar to erythrocytes, platelet morphology and function can be affected by the status of the blood vessel through which they traverse. Platelets normally circulate in a resting, nonactivated state and contain numerous intracellular granules. During activation, platelets adhere to the endothelial surface and degranulate, releasing a myriad of growth factors and cytokines. In mice, pregabalin increased platelet counts and platelet activation and altered platelet aggregation and morphology within 1 month of compound administration and, therefore, provides biomarkers of ongoing platelet-endothelial interactions. Increased number of platelets express P-selectin, a marker of platelet activation, in pregabalin-treated mice. The key cell-cell communication functions of P-selectin are (1) mediating diapedesis of neutrophils, (2) facilitating attachment of neutrophils to endothelial cells, which can induce vascular damage, and (3) priming monocytes and neutrophils to produce increased quantities of superoxide anion (Mannaioni et al., 1997; Onder et al., 1997; Page, 1989) . The increases in peripheral platelet count and activation status may therefore contribute to the migration of myeloid cells from the bone marrow to the peripheral blood, as evidenced by increased WBC and neutrophils in pregabalin-treated mice compared with control mice. In contrast to the elevated platelet count in mice, pregabalin decreases platelet counts in rats.
Enhanced proliferation of the specific target cell is a central premise surrounding nongenotoxic tumor formation. Pregabalin's effects on endothelial cell proliferation are described in an accompanying manuscript . Endothelial cell proliferation is driven by a variety of angiogenic growth factors. Pregabalin increased VEGF and bFGF in bone marrow and spleen and increased VEFGR2 in liver in the mouse, but had no effect on these parameters in rats (Fig. 7) . In the NTP review of mouse hemangiosarcomas, Siesky et al., (2001) suggested an indirect link may exist whereby activated Kupffer cells induce the release of cytokines and growth-regulatory molecules that contribute to DNA damage and synthesis and subsequently endothelial cell proliferation. Macrophages also contain a wealth of bioactive products that could more directly contribute to enhanced endothelial cell proliferation. Macrophages contribute to tumorigenic processes that are both dependent on and independent of iron. Macrophage secretion of bioactive contents is stimulated by phagocytosis, a process that is clearly evident in mice treated with pregabalin, but absent in rats. Typical effects elicited by macrophage products include increased activation, chemotaxis, invasiveness, angiogenesis, and proliferation. Increased endothelial cell proliferation has been linked to macrophage secretions, including bFGF, VEGF, G-CSF (granulocyte colony-stimulating factor), GM-CSF (granulocyte macrophage colony-stimulating factor), PDGF, and insulin-like growth factor (Sunderkotter et al., 1994) . Generation of reactive oxygen species has been implicated in damage to cellular lipids, proteins, carbohydrates, and DNA, particularly when cytoprotective mechanisms such as antioxidant activity are overwhelmed (Meneghini, 1997) . Because DNA is a target for iron-induced damage, it has also been implicated in malignant transformation (De Freitas and Meneghini, 2001 ). Mice, but not rats, demonstrate a temporal increase in macrophages in bone marrow, liver, and spleen consistent with the hemangiosarcoma-formation pattern in mice.
In 2009, a unified MOA framework for induction of hemangiosarcoma by genotoxic compounds was proposed, whereby five components appeared to be shared across the diverse compounds that induced hemangiosarcoma (Cohen et al., 2009) . Specifically, agents that induce hemangiosarcoma appear to initiate events that lead to local tissue hypoxia and macrophage activation. These two changes increase angiogenic growth factors. Cohen et al. (2009) hypothesized that dysregulated angiogenesis and/or dysregulated erythropoiesis leads to hemangiosarcoma. We have also presented evidence that pregabalin treatment induced dysregulated erythropoiesis and increased angiogenic growth factor expression in tissues where hemangiosarcoma is formed in mice, consistent with the unified MOA framework.
CONCLUSION
Persistent pregabalin-induced alterations in serum bicarbonate, respiratory function, and blood gas parameters, without adequate compensatory mechanisms, in mice are consistent with the development of tissue hypoxia, a change that could exacerbate nongenotoxic induction of vascular tumors through increased endothelial cell proliferation. Additionally, evidence for dysregulated erythropoiesis, macrophage activation, and increased angiogenic growth factors was observed in mice but not in rats. Because these effects occurred early, they may potentially be linked to hemangiosarcoma formation. Mice appear to be uniquely sensitive to these changes.
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